Kati Medical Technology

Nanjing Kati Medical Technology (Kati Medical) is a clinical-stage biotechnology company specializing in the research and development of innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies, primarily targeting solid tumors. Founded in 2017 by Dr. Wang Enxiu, a former key researcher in the Carl June laboratory at the University of Pennsylvania, the company leverages its proprietary DAP-CAR technology platform to improve the efficacy and persistence of CAR-T cells within the immunosuppressive tumor microenvironment. Its pipeline features several promising candidates, including KT032 targeting Mesothelin for ovarian and pancreatic cancers and KT051 targeting Claudin 18.2 for gastric and pancreatic cancers. Kati Medical also explores metabolic reprogramming through strategic collaborations to enhance cell therapy outcomes. Headquartered in the Nanjing Biopharmaceutical Valley, the company has progressed multiple programs into investigator-initiated trials and clinical development.